Middle East respiratory syndrome: pathogenesis and therapeutic developments

Future Virol. 2019 Apr;14(4):237-246. doi: 10.2217/fvl-2018-0201. Epub 2019 Apr 18.

Abstract

The first case of Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in the year 2012, which spread rapidly and increased to more than 2200 in 2018. This highly pathogenic virus with high mortality rate is among one of the major public health concerns. Saudi Arabia remains to be the most affected region with the majority of MERS-CoV cases, and currently, no effective drugs and vaccines are available for prevention and treatment. A large amount of information is now available regarding the virus, its structure, route of transmission and its pathophysiology. Therefore, this review summarizes the current understanding of MERS-CoV's pathogenesis, treatment options and recent scientific advancements in vaccine and other therapeutic developments, and the major steps taken for MERS prevention control.

Keywords: Arabian Peninsula; MERS; SARS; Saudi Arabia; WHO; coronavirus; global; macrophages; therapeutic; vaccine.

Publication types

  • Review